| 1 |
33495313 | Abiraterone Acetate Induces CREB1 Phosphorylation and Enhances the Function of the CBP-p300 Complex, Leading to Resistance in Prostate Cancer Cells. | 2021 Apr 1 |
1 |
| 2 |
34041015 | Synergistic Effect of Statins and Abiraterone Acetate on the Growth Inhibition of Neuroblastoma via Targeting Androgen Receptor. | 2021 |
1 |
| 3 |
34333840 | Warning against second-generation antiandrogen for metastatic castration sensitive prostate cancer. | 2021 Nov |
1 |
| 4 |
34493283 | The effects of selected inhibitors on human fetal adrenal steroidogenesis differs under basal and ACTH-stimulated conditions. | 2021 Sep 8 |
2 |
| 5 |
31611636 | Exposure-response analyses of abiraterone and its metabolites in real-world patients with metastatic castration-resistant prostate cancer. | 2020 Jun |
1 |
| 6 |
32045360 | Abiraterone acetate treatment lowers 11-oxygenated androgens. | 2020 Apr |
2 |
| 7 |
32581567 | Association Between CYP17A1, CYB5A Polymorphisms and Efficacy of Abiraterone Acetate/Prednisone Treatment in Castration-Resistant Prostate Cancer Patients. | 2020 |
2 |
| 8 |
32911627 | Adherence Measures for Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate plus Prednisone: Results of a Prospective, Cluster-Randomized Trial. | 2020 Sep 8 |
1 |
| 9 |
33004739 | CYP17 inhibitors improve the prognosis of metastatic castration-resistant prostate cancer patients: A meta-analysis of published trials. | 2020 Sep |
1 |
| 10 |
30427533 | A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer. | 2019 Feb 15 |
1 |
| 11 |
30537624 | An LC-MS/MS method for quantification of abiraterone, its active metabolites D(4)-abiraterone (D4A) and 5α-abiraterone, and their inactive glucuronide derivatives. | 2019 Jan 1 |
2 |
| 12 |
30770950 | Abiraterone acetate exerts a cytotoxic effect in human prostate cancer cell lines. | 2019 Jun |
2 |
| 13 |
28715929 | Molecular interactions of bisphenols and analogs with glucocorticoid biosynthetic pathway enzymes: an in silico approach. | 2018 Jan |
1 |
| 14 |
29438990 | Nuclear Receptor LRH-1 Functions to Promote Castration-Resistant Growth of Prostate Cancer via Its Promotion of Intratumoral Androgen Biosynthesis. | 2018 May 1 |
1 |
| 15 |
29541468 | Baseline neutrophil-to-lymphocyte ratio predicts the prognosis of castration-resistant prostate cancer treated with abiraterone acetate. | 2018 Apr |
1 |
| 16 |
30029732 | Dehydroepiandrosterone (DHEA)-SO4 Depot and Castration-Resistant Prostate Cancer. | 2018 |
1 |
| 17 |
26862015 | Steroid 17-hydroxylase and 17,20-lyase deficiencies, genetic and pharmacologic. | 2017 Jan |
2 |
| 18 |
27753628 | Study of cases of abiraterone discontinuation due to toxicity in pre-chemotherapy after 1 year's experience. | 2017 Dec |
1 |
| 19 |
28819727 | Abiraterone Acetate: A Review in Metastatic Castration-Resistant Prostrate Cancer. | 2017 Sep |
2 |
| 20 |
28852974 | Low dose versus standard dose of corticosteroids in the management of adverse events of special interest from abiraterone acetate: data from a literature-based meta-analysis. | 2017 Aug 29 |
1 |
| 21 |
29110971 | The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: An indirect comparison of randomized controlled trials. | 2017 Dec |
1 |
| 22 |
26965562 | Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. | 2016 Sep |
1 |
| 23 |
26971191 | A single-center experience with abiraterone as treatment for metastatic castration-resistant prostate cancer. | 2016 Jul |
1 |
| 24 |
26971992 | Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: A meta-analysis of published trials. | 2016 May |
1 |
| 25 |
27007943 | Cytochrome P450 17A1 Inhibitor Abiraterone Acetate Counteracts the Heat Shock Protein 27's Cell Survival Properties in Prostate Cancer Cells. | 2016 |
1 |
| 26 |
27278777 | Association of early PSA decline and time to PSA progression in abiraterone acetate-treated metastatic castration-resistant prostate cancer; a post-hoc analysis of Japanese phase 2 trials. | 2016 Jun 8 |
1 |
| 27 |
27358844 | Feasibility of abiraterone acetate treatment in patients with metastatic castration-resistant prostate cancer and atrial fibrillation. | 2016 Jun |
1 |
| 28 |
27482286 | CYP17 inhibitors in prostate cancer: latest evidence and clinical potential. | 2016 Jul |
2 |
| 29 |
27504016 | In Vitro and In Vivo Drug-Drug Interaction Studies to Assess the Effect of Abiraterone Acetate, Abiraterone, and Metabolites of Abiraterone on CYP2C8 Activity. | 2016 Oct |
1 |
| 30 |
27544566 | How I do it: Prescribing abiraterone acetate for metastatic castration resistant prostate cancer. | 2016 Aug |
1 |
| 31 |
27561266 | High prevalence of potential drug-drug interactions in patients with castration-resistant prostate cancer treated with abiraterone acetate. | 2016 Nov |
1 |
| 32 |
27748439 | Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer. | 2016 Oct 17 |
1 |
| 33 |
25560485 | CYP17A1 inhibitors in castration-resistant prostate cancer. | 2015 Mar |
1 |
| 34 |
25813901 | A HPLC-fluorescence method for the quantification of abiraterone in plasma from patients with metastatic castration-resistant prostate cancer. | 2015 May 1 |
1 |
| 35 |
25936418 | Pharmacokinetics, pharmacodynamics and clinical efficacy of abiraterone acetate for treating metastatic castration-resistant prostate cancer. | 2015 Jun |
1 |
| 36 |
26025264 | The development of abiraterone acetate for castration-resistant prostate cancer. | 2015 Jun |
1 |
| 37 |
26032458 | Mechanisms of drug resistance that target the androgen axis in castration resistant prostate cancer (CRPC). | 2015 Sep |
1 |
| 38 |
26082421 | Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetate. | 2015 Sep |
1 |
| 39 |
26134919 | Metastatic castration-resistant prostate cancer: targeting the mechanisms of resistance to abiraterone acetate and enzalutamide. | 2015 |
2 |
| 40 |
26814148 | Mechanisms of resistance in castration-resistant prostate cancer (CRPC). | 2015 Jun |
1 |
| 41 |
24276076 | CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents. | 2014 Jan |
1 |
| 42 |
24284787 | Differential response to abiraterone acetate and di-n-butyl phthalate in an androgen-sensitive human fetal testis xenograft bioassay. | 2014 Mar |
1 |
| 43 |
24508512 | A-ring modified steroidal azoles retaining similar potent and slowly reversible CYP17A1 inhibition as abiraterone. | 2014 Sep |
2 |
| 44 |
24759590 | Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer. | 2014 May-Jun |
1 |
| 45 |
24775307 | Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors. | 2014 Jun 1 |
1 |
| 46 |
24780050 | Abiraterone acetate to lower androgens in women with classic 21-hydroxylase deficiency. | 2014 Aug |
1 |
| 47 |
24793632 | [Abiraterone acetate (AA): current guidelines of prescription of abiraterone]. | 2014 Apr |
1 |
| 48 |
24890318 | Targeting the androgen receptor in prostate cancer. | 2014 Jul |
1 |
| 49 |
25047002 | Inhibition of the androgen receptor by mineralocorticoids at levels physiologically achieved in serum in patients treated with abiraterone acetate. | 2014 Sep |
1 |
| 50 |
25111736 | Retreatment of men with metastatic castrate-resistant prostate cancer with abiraterone. | 2014 Oct |
1 |